Sandoz's biosimilar denosumab drugs Wyost® and Jubbonti® receive European Commission approval.

From GlobeNewswire: 2024-05-22 01:00:00

Sandoz gains EC approval for biosimilar denosumab medicines, Wyost® and Jubbonti®, for cancer-related bone disease and osteoporosis treatment. These biosimilars match reference medicines Xgeva® and Prolia® in safety, efficacy, and quality. Approval aligns with Sandoz’s commitment to provide sustainable treatment options. The approval addresses the significant disease burden of cancer-related bone events and osteoporosis in Europe, impacting millions of patients. Both Wyost® and Jubbonti® contain denosumab and have the same dosage form and administration as their reference medicines. These biosimilars are key drivers in Sandoz’s growth strategy, expected to launch from November 2025.



Read more at GlobeNewswire: Sandoz receives European Commission approval for Wyost® and